# Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

> **NCT01000896** · PHASE1 · WITHDRAWN · sponsor: **AstraZeneca** · enrollment: 27 (estimated)

## Conditions studied

- Cancer
- Non Small Cell Lung Cancer
- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** AZD0530
- **DRUG:** Carboplatin
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT01000896
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-01
- **Primary completion:** 2010-09
- **Final completion:** 2011-03
- **Target enrollment:** 27 (ESTIMATED)
- **Why stopped:** AstraZeneca has discontinued the development of AZD0530. No new AstraZeneca-sponsored clinical studies will be initiated..
- **Last updated:** 2010-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01000896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01000896, "Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01000896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*